

I Fw mrg  
1647

Docket No. 0575/59472-A-PCT-US/JPW/AJM/JCS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Stern, et al.  
Serial No. : 10/049,893  
Filed : July 22, 2002  
For : METHODS OF INHIBITING BINDING OF BETA-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF

1185 Avenue of the Americas  
New York, New York 10036  
May 10, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references, which were cited in a February 21, 2005 Supplementary Partial Search Report issued by the European Patent Office in connection with related European Patent Application No. 00955464.3.

This Information Disclosure Statement is submitted as a supplement to the Information Disclosure Statement filed September 20, 2002. The applicants direct the Examiner's attention to the following references which are listed on the enclosed PTO-1449 form attached hereto as **Exhibit 1**.

NOT AVAILABLE COPY



Applicants: David Stern, et al.  
Serial No.: 10/049,893  
Filed: July 22, 2002  
Page 2

1. February 21, 2005 Communication enclosing a Supplementary Partial European Search Report issued in connection with related European Patent Application No. 00955464.3, on behalf of The Trustees of Columbia University in the City of New York, regional stage of PCT International Application No. PCT/US00/22059, filed August 11, 2000 (**Exhibit 2**);
2. Zhu, et al., "RAGE interaction with Abeta fibrils activates signal transduction mechanisms and results in apoptosis activation of MAP kinases and nuclear translocation of NF-EkB," Society for Neuroscience Abstracts 24: 228 (1998) (**Exhibit 3**);
3. Yan, et al., "RAGE and Amyloid-Beta Peptide Neurotoxicity in Alzheimer's Disease," Nature: 382: 685-691 (1996) (**Exhibit 4**);
4. The Trustees of Columbia University in the City of New York, International Patent Application No. WO 99/18987 published April 22, 1999 (**Exhibit 5**);
5. The Trustees of Columbia University in the City of New York, International Patent Application No. WO 97/26913 published July 31, 1997 (**Exhibit 6**);
6. Yan, et al., "Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide," Biochimica Et Biophysica Acta. Molecular Basis of Disease 1502: 145-157 (2000) (**Exhibit 7**);

Applicants: David Stern, et al.  
Serial No.: 10/049,893  
Filed: July 22, 2002  
Page 3

7. Yan, et al., "Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis," Nature Medicine 6: 643-651 (2000) (**Exhibit 8**);
8. Sousa, et al., "Interaction of the receptor for advanced glycation endproducts (RAGE) with transthyretin triggers nuclear transcription factor kB (NF0kB) activation," Laboratory Investigation 80: 1101-1110 (2000) (**Exhibit 9**); and
9. The Picower Institute for Medical Research, International Patent Application No. WO 95/20979 published August 10, 1995 (**Exhibit 10**).

Applicants request that the Examiner review the references and make them of record in the subject application.


Applicants: David Stern, et al.  
Serial No.: 10/049,893  
Filed: July 22, 2002  
Page 4



Applicants are filing this Information Disclosure Statement under 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
Tel. No. (212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
 5/10/05  
Alan J. Morrison Date  
Registration No. 37,399

Form PTO-1449 MAY 13 2005 U.S. Department of Commerce Patent and Trademark Office <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	Application Number	10/049,893
	Filing Date	July 22, 2002
	First Named Inventor	David Stern, et al.
	Art Unit	
	Examiner Name	
Attorney Docket No.		59472-A-PCT-US/JPW/AJM/JCS

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
		WO 99/18987	4/22/1999	The Trustees of Columbia University in the City of New York	
		WO 97/26913	7/31/1997	The Trustees of Columbia University in the City of New York	
		WO 95/20979	8/10/1995	The Picower Institute for Medical Research	

EXAMINER  
SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Stern, et al.  
 Serial No. : 10/049,893  
 Filed: July 22, 2002  
 Exhibit 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Application Number	10/049,893
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Filing Date	July 22, 2002
		First Named Inventor	David Stern, et al.
		Art Unit	
		Examiner Name	
		Attorney Docket No.	59472-A-PCT-US/JPW/AJM/JCS

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		February 21, 2005 Communication enclosing a Supplementary Partial European Search Report issued in connection with related European Patent Application No. 00955464.3, on behalf of The Trustees of Columbia University in the City of New York, regional stage of PCT International Application No. PCT/US00/22059, filed August 11, 2000	
		Zhu, et al., "RAGE interaction with Abeta fibrils activates signal transduction mechanisms and results in apoptosis activation of MAP kinases and nuclear translocation of NF-EkB," Society for Neuroscience Abstracts 24: 228 (1998)	
		Yan, et al., "RAGE and Amyloid-Beta Peptide Neurotoxicity in Alzheimer's Disease," Nature: 382: 685-691 (1996)	
		Yan, et al., "Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide," Biochimica Et Biophysica Acta. Molecular Basis of Disease 1502: 145-157 (2000)	
		Yan, et al., "Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis," Nature Medicine 6: 643-651 (2000)	
		Sousa, et al., "Interaction of the receptor for advanced glycation endproducts (RAGE) with transthyretin triggers nuclear transcription factor kB (NF0kB) activation," Laboratory Investigation 80: 1101-1110 (2000)	

EXAMINER  
SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.